SRPT•benzinga•
Cantor Fitzgerald Maintains Overweight on Sarepta Therapeutics, Lowers Price Target to $81
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 7, 2025 by benzinga